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Purpose: To determine the role of the recently discovered primary open angle glaucoma (POAG) risk factor mapped to
chromosome 7q31 in glaucoma patients from Iowa and to determine the expression pattern of genes in the locus in human
eyes.
Methods: A cohort of 545 POAG patients and 297 control subjects from Iowa were genotyped with a single nucleotide
polymorphism (SNP; rs4236601) in the chromosome 7q31 locus using a quantitative polymerase chain reaction (PCR)
assay. The expression of genes within the 7q31 locus, caveolin-1 (CAV1) and caveolin-2 (CAV2) in human eyes was
investigated with immunohistochemistry.
Results: The minor allele frequency (MAF) of rs4236601 was 27% in control subjects and 29% in POAG patients. We
detected no statistical difference when we compared the allele frequencies of rs4236601 between POAG patients and
control subjects (p=0.5). Similarly, we detected no statistical difference in the frequency of the three possible rs4236601
genotypes between patients and controls (p=0.22). Immunohistochemistry showed caveolin expression in human retina,
ciliary muscle, trabecular meshwork, and Schlemm’s canal. In our small cohort of donor eyes, the genotype of rs4236601
did not obviously influence labeling intensity or distribution of CAV1 and CAV2 in the retina.
Conclusions: A genome-wide association study of subjects from Iceland mapped the first common genetic risk factor for
POAG to a small region of the genome on chromosome 7q31 that contains the caveolin genes CAV1 and CAV2. We were
unable to detect this association in our patients from Iowa, suggesting that this risk factor may not have a strong effect in
all populations.
The glaucomas are a group of eye diseases that primarily
affect the optic nerve and retinal ganglion cells and are a
common cause of vision loss and blindness. Current estimates
suggest that over 60 million people have glaucoma worldwide
[1]. Glaucoma is defined by progressive cupping of the optic
disc and a corresponding loss of visual field. Several risk
factors for glaucoma have been identified including age, race,
family  history,  intraocular  pressure  (IOP),  and  corneal
thickness. The most common form of glaucoma in the United
States is primary open angle glaucoma (POAG) [2]. A subset
of  POAG  that  occurs  with  a  maximum  IOP  below  an
arbitrarily  threshold  of  21  mmHg  is  often  termed  normal
tension glaucoma (NTG).
Genetic  variants  have  also  been  shown  to  have  a
significant role in the pathogenesis of POAG. Studies of rare
families have mapped the position of 14 POAG genes to small
regions of the genome [3-6] and glaucoma-causing genes have
been discovered in two of these loci, myocilin (MYOC) [7]
and  optineurin  (OPTN)  [8].  Mutations  in  MYOC  are
associated with POAG that is characterized by high IOP and
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strong family history and are responsible for approximately
4% of POAG cases worldwide. Mutations appear to cause
myocilin  protein  to  become  misfolded  which  leads  to
increases  in  outflow  resistance,  elevated  IOP,  and
subsequently the development of POAG [9]. Mutations in
OPTN have been associated with rare cases of NTG [8,10].
The protein encoded by OPTN is involved in many biologic
processes  including  some  that  lead  to  apoptosis  [11,12],
however, the mechanism by which mutations in this gene
cause glaucoma is unknown. An additional gene, WD repeat
domain 36 (WDR36), was identified by family-based studies.
However, its role in glaucoma pathogenesis is controversial
[13-17].  These  studies  have  identified  high-penetrance
mutations that cause glaucoma in a relatively small proportion
of POAG cases. Most carriers of OPTN and MYOC mutations
develop glaucoma and asymptomatic carriers are rare.
Recently,  a  population-based  study  of  glaucoma
identified the first common genetic risk factor for POAG. A
genome-wide association study of 1,263 POAG subjects and
34,877 control subjects from Iceland by Thorleifsson and
coworkers  [18]  identified  a  region  of  the  genome  on
chromosome  7q31  that  is  associated  with  glaucoma.  The
specific DNA variation that confers risk for POAG in this
locus is unknown. Although, the chromosome 7q31 locus
spans the caveolin 1 (CAV1) and caveolin 2 (CAV2) genes, no
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430DNA variations in these genes were found to be associated
with POAG. However, the minor allele of one genetic marker,
rs4236601,  was  tightly  associated  with  POAG  with  a
p=5.0×10−10. When Thorleifsson and coworkers [18] tested a
second cohort of 4,239 POAG patients and controls from
Sweden, the UK, and Australia with the rs4236601 marker,
the  association  with  glaucoma  was  confirmed  but  was
statistically much weaker (p=0.0015). When a third cohort of
POAG patients and controls from Hong Kong and Shantou
China were studied, the association between rs4236601 and
glaucoma  was  again  confirmed  with  similar  statistical
significance (p=0.003) [18]. The role of the POAG risk allele
at the chromosome 7q31 locus appears to have significance
that varies between populations. Consequently, we set out to
investigate the importance of this glaucoma risk factor by
genotyping our cohort of POAG patients and control subjects
from Iowa at the rs4236601 marker. We also examined the
expression of the two genes in the chromosome 7q31 locus
(CAV1 and CAV2) using an immunohistochemistical study of
human donor eyes.
METHODS
The  study  was  approved  by  the  University  of  Iowa’s
Institutional  Review  Board  and  informed  consent  was
obtained from study participants.
A cohort of 545 subjects were examined by fellowship-
trained  glaucoma  specialists  and  received  complete
ophthalmic  examinations  (including  gonioscopy,
standardized visual field testing, and stereoscopic optic nerve
examination).  Subjects  were  diagnosed  with  open  angle
glaucoma  when  characteristic  optic  nerve  damage  and
corresponding visual field defects were detected in at least one
eye and the maximum IOP was greater than 21 mmHg as
previously described [19]. A cohort of 297 unrelated normal
subjects from Iowa that had no evidence of glaucomatous
optic nerve damage and had IOP <22 mmHg were enrolled as
control  subjects.  Normal  subjects  were  not  specifically
evaluated for the presence of exfoliation syndrome. Blood
samples were obtained from study participants and DNA was
prepared using a non-organic method [20].
The power of this Iowa sample to detect a disease odds
ratio of 1.6 is 87% at a significance level α=0.05, 70% at
α=0.01. For a disease odds ratio of 1.8, it is 97% at α=0.05,
88% at α=0.01. For a disease odds ratio of 1.4, it is 62% at
α=0.05, 38% at α=0.01. Power calculations were made using
an online power calculator for for logistic regression with
binary covariates. The value of MAF was set at 0.28, between
the MAF in Iowa cases and in Iowa controls.
Subjects  were  genotyped  at  single  nucleotide
polymorphism  (SNP)  rs4236601  with  a  quantitative
polymerase  chain  reaction  (PCR)  assay  using  the
manufacturer’s  protocol  (TaqMan;  Applied  Biosystems,
Carlsbad,  CA).  Genotype  calls  were  confirmed  by  DNA
sequencing  in  10  subjects  using  standard  conditions  and
primers  that  are  available  on  request.  The  frequency  of
rs4236601  alleles  and  genotypes  were  compared  between
patients and controls using Fisher’s exact test and the software
package R. A threshold p<0.05 was considered significant.
Retinal tissue from human eye donors without reported
ocular  diseases  was  obtained  and  preserved  in  4%
paraformaldehyde  within  5  h  postmortem.  Following
genotyping  for  rs4236601,  six  donors  were  chosen  for
immunohistochemical  analysis,  three  of  which  were
homozygous  for  each  genotype.  Tissue  was  embedded  in
optimum cutting temperature medium (OCT; Ted Pella, Inc.,
Redding, CA), frozen and sagittal sections at a thickness of
7 μm were obtained. Caveolin 1 was detected using a goat
primary  antibody  (1:200  dilution;  Abcam,  Cambridge,
MA) and a Cy3 conjugated secondary antibody (Invitrogen,
Carlsbad, CA). Caveolin 2 was detected using a rabbit primary
antibody  (1:200  dilution;  Abcam)  and  a  Cy5  conjugated
secondary antibody (Invitrogen). Images were counterstained
with 4’-6-Diamidino-2-phenylindole (DAPI) for orientation.
Negative controls included sections incubated with secondary
antibody alone. The expression of caveolin 1 and caveolin 2
were each studied in the anterior segments of two donor eyes
using the same immunohistochemistical methods.
RESULTS
A cohort of 545 POAG patients and 297 control subjects from
Iowa was genotyped with the genetic marker, rs4236601, that
was previously associated with POAG [18]. The size of this
cohort has a 87% chance of detecting an association with
POAG that has an odds ratio of 1.6 or greater with a p<0.05.
Similarly, our study has 62% chance to detect an association
with an odds ratio of 1.4 or greater (p<0.05), which is similar
to the association detected by Thorleifsson et al. [18] in their
cohort of Icelandic subjects.
The minor allele frequency of rs4236601 in our cohort
from Iowa is 28.5% in the POAG patients and 26.9% in
control  subjects  (Table  1).  No  significant  difference  was
detected in allele frequency between the POAG patients and
controls (p=0.50). Similarly the frequency of each of the three
possible genotypes of rs4236601 were compared between
POAG  patients  and  controls  (Table  1)  and  no  significant
difference was detected (p=0.22).
Immunohistochemical analysis of human retinal sections
from  6  donors  indicate  that  Caveolin  1  is  prominently
localized in association with the ganglion cell layer (Figure
1A) Perivascular labeling of small and large retinal vessels,
the  nerve  fiber  layer  and  inner  plexiform  layer  was  also
occasionally  observed.  Caveolin  2  immunoreactivity  was
most pronounced throughout the nerve fiber and ganglion cell
layers  (Figure  1C).  Weak  immunoreactivity  was  also
observed in the inner and outer plexiform and nuclear layers,
but  not  in  association  with  photoreceptor  inner  and  outer
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431segments. A radial labeling pattern was evident in the inner
plexiform layer, suggesting that Muller cells are at least in part
responsible for Caveolin 2 expression in the retina. Retinal
vascular elements were variably immunoreactive. We did not
observe  obvious  qualitative  differences  in  the  labeling
patterns and intensity when the retinas of donors homozygous
for the minor and major alleles were compared to each other.
Immunohistochemical analysis of the anterior segments of 2
donors demonstrated that Caveolin 1 and Caveolin 2 are both
localized to Schlemm’s canal, while Caveolin 1 is also present
in  the  trabecular  meshwork  (TM)  and  Caveolin  2  is  also
present in the ciliary muscle (Figure 2).
DISCUSSION
POAG is a heterogeneous collection of retinal ganglion cell
and optic nerve diseases. Studies of rare, large POAG families
have provided evidence for the existence of at least 14 genes
that when defective or mutated can cause glaucoma without
many contributions from other genes or the environment. Two
of  these  high  penetrance  glaucoma  genes,  MYOC  and
OPTN, are responsible for around 4% of POAG cases overall.
A significant fraction of the remaining cases of POAG are
likely caused by the combined influence of mutations in many
genes and the action of environmental factors. Such genetic
factors may each contribute small risk for developing POAG
on their own and will be frequently observed in subjects that
never develop glaucoma. Thorleifsson et al. [18] recently
mapped the first of these common genetic risk factors for
POAG to a small region of chromosome 7q31 with a genome-
wide  association  study  of  subjects  from  Iceland.  The
chromosome  7q31  locus  is  tagged  by  the  minor  allele  of
rs4236601 and contains two genes, CAV1 and CAV2, although
no glaucoma-associated mutations in these genes have been
found to date [18]. The glaucoma risk factor that is in linkage
disequilibrium with the minor allele of rs4236601 has not yet
been discovered.
Given the recent association study results, CAV1 and
CAV2 have been implicated in glaucoma pathogenesis. The
TABLE 1. ALLELE AND GENOTYPE FREQUENCIES OF SNP RS4236601 IN POAG PATIENTS AND CONTROL SUBJECTS FROM IOWA.
Alleles POAG (n=545) NL (n=297) Genotypes POAG (n=545) NL (n=297)
G 779 (71.5%) 434 (73.1%) G/G 274 (50%) 163 (55%)
A 311 (28.5%) 160 (26.9%) A/G 231 (42%) 108 (36%)
      A/A 40 (7.3%) 26 (8.8%) p-value=0.50
Figure 1. Caveolin 1 and 2 in the human
retina. Immunohistochemical detection
of Caveolin 1 (A and B) and Caveolin 2
(C and D) in the human retina. Negative
controls with no primary antibody (B
and  D)  revealed  only  minor  cross
reactivity of the secondary antibodies.
GCL=ganglion  cell  layer,  INL=Inner
nuclear layer, ONL=outer nuclear layer,
OS=Outer segments.
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p-value=0.22family of caveolin genes encode proteins that form caveolae,
invaginated plasma membrane structures that are believed to
have an important role in the transport of macromolecules
across  membranes  (transcytosis)  and  influence  signaling
pathways by regulating the positioning of signaling molecules
in the membrane. Caveolin 1 and caveolin 2 are expressed in
non-muscle cells while caveolin 3 is present in skeletal and
some  smooth  muscle  cells  [21].  Although  no  glaucoma-
causing mutations have been identified in either CAV1 or
CAV2  to  date,  the  results  of  the  recent  genome-wide
association study suggests their existence. The mechanism by
which defects in either CAV1 or CAV2 might cause glaucoma
is unknown, but it has been hypothesized that such mutations
might  lead  to  glaucoma  by  altering  nitric  oxide  or
transforming  growth  factor-β  (TGF-β)  signal  transduction
[18].
A  series  of  prior  studies  have  shown  that  CAV1  and
CAV2 are expressed in the eye at the RNA [22,23] and protein
[24] levels. We investigated the ocular expression of these
genes in the human retina. Immunohistochemical analysis
demonstrated  that  both  caveolin  1  and  caveolin  2  are
expressed throughout the inner retina. Immunoreactivity of
caveolin 1 was mainly observed in the ganglion cell layer,
consistent  with  a  possible  role  in  glaucoma.  Perivascular
labeling in the retina was also observed. In prior studies,
CAV1  knockout  mice  were  shown  to  have  vascular
permeability defects [25] which also might negatively affect
retinal ganglion cell survival. Similar to previous studies in
the  rat  [26],  our  studies  of  human  retina  found
immunostaining of small vessels with caveolin 2, as well as
Müller and retinal ganglion cells of the inner retina. These
findings are largely in accord with a previous study of human
melanoma  eyes  [24].  Futhermore,  the  caveolins  are  also
expressed in the ciliary muscle, the TM, and Schlemm’s canal,
ocular tissues that are involved in IOP regulation and the
pathogenesis of glaucoma. Expression in human retina and
tissues of the aqueous humor outflow pathway does not prove
that either caveolin 1 or caveolin 2 has a role in glaucoma
pathogenesis.  However,  these  expression  data  do  provide
some  support  to  the  hypothesis  that  variants  in  CAV1  or
CAV2  may  be  the  source  of  glaucoma  risk  mapped  to
chromosome 7q31 [18]. Genotype at this locus did not appear
to have a clearly recognizable effect on the pattern or intensity
of labeling in the retinas of our small series of human donor
eyes.
The  minor  allele  of  rs4236601  marks  the  as  yet
undiscovered  POAG  risk  factor  in  the  chromosome  7q31
locus. However, there is great variability in the minor allele
frequency (MAF) of this marker between the populations in
the HapMap database and also between populations studied
by Thorleifsson et al. [18]. HapMap data shows that Asian
populations have low minor allele frequencies of rs4236601
(0%–1.4%), while African populations have high minor allele
frequencies  (30%–43%)  and  Hispanic  and  non-Hispanic
Caucasians have intermediate minor allele frequencies (22%
and 28%–29%, respectively) [27]. The variable MAF between
populations with different racial and ethnic background was
also  detected  in  the  report  by  Thorleifsson  et  al.  [18].
Furthermore, the strongest association detected in the 7q31
locus was a result of a relatively small difference in MAF of
rs4236601  between  POAG  patients  (28.7%)  and  control
subjects (22.8%) from Iceland [18]. Even smaller differences
in MAF between POAG patients and controls were detected
in the replication cohorts of this study. The difference in MAF
between POAG patients and controls from the UK, Australia,
and  China  was  only  0.9%–2.6%,  2.1%–4.7%,  and  1.3%–
Figure 2. Caveolin 1 and 2 in the human iridocorneal angle. Immunohistochemical detection of Caveolin 1 (A) and Caveolin 2 (B) in the
iridocorneal angle. Caveolin 1 reactivity was mainly associated with the trabecular meshwork cells lining the trabecular meshwork beams
(Arrowhead) and Schlemm’s canal. Caveolin 2 is mainly detected in Schlemm’s canal and the longitudinal ciliary muscle. (SC: Schlemm’s
canal, TM: Trabecular meshwork, Magnification: (A) 400×, (B) 200×).
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4331.6%, respectively [18]. Together these data suggest that the
glaucoma risk factor in the chromosome 7q31 region may
have a stronger effect in some populations than others.
We set out to determine the role of the chromosome 7q31
risk allele (rs4236601) in our cohort of patients and controls
from Iowa. Our study had sufficient power to replicate the
association between rs4236601 and POAG reported in the
cohort of subjects from Iceland. However, we detected no
significant  difference  (p=0.50)  in  the  MAF  of  rs4236601
between POAG patients (28.5%) and control subjects (26.9%)
from Iowa. Similarly, we detected no significant difference in
rs4236601 genotypes between POAG patients and controls
from  Iowa  (p=0.22).  Our  association  study  results  with
rs4236601 (p=0.5) differ considerably from those reported
with  the  Icelandic  population  in  the  original  report
(p=5.0×10−10) [18].
There  are  at  least  three  possibilities  that  together  or
individually could explain the disparity between our results
and  those  of  the  original  report.  First,  is  the  very  large
difference in sample size (n=842 from Iowa versus n=36,140
from Iceland). However, this does not seem to be the complete
explanation because if the Iowa cohort were to be expanded
to  the  same  size  as  the  Iceland  cohort  (n=36,140)  while
maintaining the observed allele frequency difference between
POAG patients and controls at rs4236601, it would still fail
to produce a significant p-value (p=0.078).
Second, it is possible that the difference in association
study  results  might  be  due  in  part  to  an  enrollment  bias
between patients and controls. The large difference in allele
frequencies of rs4236601 between ethnic and racial groups in
both HapMap and Thorleifsson’s original report suggests the
potential for artificially skewed allele frequencies if patient
and control populations aren’t well matched. One possible
source of such an enrollment bias is the presence of differing
frequencies of exfoliation syndrome in patients and controls.
In both the current study and the original report [18], attempts
were  made  to  exclude  subjects  with  known  exfoliation
syndrome from the POAG patient cohorts but not from the
control cohorts. This specific enrollment bias is likely to be
present in all association studies of POAG that use control
groups that were not specifically evaluated for exfoliation
syndrome. However, it is likely to have a much stronger effect
in  populations  with  a  higher  frequency  of  exfoliation
syndrome, such as cohorts from Iceland. It is possible that
some of the difference in our association study results are due
to this enrollment bias coupled with the significant differences
in the population prevalence of exfoliation syndrome between
Iceland (33% [28]) and in the United States (1.6 to 5.0%
[29,30]). Since the MAF of rs4236601 varies greatly between
populations,  associations  based  on  this  SNP  may  be
particularly sensitive to ethnic biases.
Finally,  the  chromosome  7q31  glaucoma  risk  factor
might be more important in some ethnic populations than
others  due  to  a  founder  effect.  The  minor  allele  of
rs4236601 might be more prevalent among POAG patients in
Iceland than in other countries because a larger proportion of
Icelandic patients descended from founders with a POAG risk
allele in linkage disequilibrium with rs4236601.
Overall, these data and observations imply that a POAG
risk allele at the 7q31 locus is not strongly associated with
glaucoma in the Iowa population. Future research including
more replication studies, the identification of the specific risk
allele  in  the  chromosome  7q31  locus,  and  ultimately,
functional studies will clarify the role of this risk factor in the
pathogenesis of POAG.
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